Jibran Durrani

443 total citations
24 papers, 146 citations indexed

About

Jibran Durrani is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jibran Durrani has authored 24 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 8 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Jibran Durrani's work include Acute Myeloid Leukemia Research (11 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Jibran Durrani is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Jibran Durrani collaborates with scholars based in United States, Germany and Italy. Jibran Durrani's co-authors include Jaroslaw P. Maciejewski, Faizan Malik, Emma M. Groarke, Valeria Visconte, Roomasa Channa, Khabir Ahmad, Hetty E. Carraway, Mikkael A. Sekeres, Hassan Awada and Ashwin Kishtagari and has published in prestigious journals such as Blood, Journal of Leukocyte Biology and British Journal of Haematology.

In The Last Decade

Jibran Durrani

23 papers receiving 144 citations

Peers

Jibran Durrani

HEMAT

GENET

IMMUN

RNMI

Tamami Yoshitama Japan

Patrick Harrington United Kingdom

Juan José Rodríguez‐Sevilla Spain

Fabio De Gennaro Italy

Rumi Clare Canada

George Chan New Zealand

Ambra Paolini Italy

Alessandra Borchiellini Italy

Mehmet Türe Türkiye

Po‐Shen Ko Taiwan

Tamami Yoshitama Japan

Jibran Durrani

61 ×0.9

HEMAT

41 ×1.3

GENET

40 ×1.3

IMMUN

15 ×0.6

6 ×0.4

RNMI

Citations per year, relative to Jibran Durrani Jibran Durrani (= 1×) peers Tamami Yoshitama

Countries citing papers authored by Jibran Durrani

Since Specialization

Citations

This map shows the geographic impact of Jibran Durrani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jibran Durrani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jibran Durrani more than expected).

Fields of papers citing papers by Jibran Durrani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jibran Durrani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jibran Durrani. The network helps show where Jibran Durrani may publish in the future.

Co-authorship network of co-authors of Jibran Durrani

This figure shows the co-authorship network connecting the top 25 collaborators of Jibran Durrani. A scholar is included among the top collaborators of Jibran Durrani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jibran Durrani. Jibran Durrani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Glass, J. David, Xingmin Feng, Jibran Durrani, et al.. (2025). Macrophage polarization, inflammatory monocytes, and impaired MDSCs are associated with murine and human immune aplastic anemia. Journal of Leukocyte Biology. 117(6). 1 indexed citations

Durrani, Jibran, Xingmin Feng, J. David Glass, et al.. (2024). Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure. Blood. 144(Supplement 1). 1309–1309. 1 indexed citations

Durrani, Jibran, Ruba Shalhoub, Jennifer Lotter, et al.. (2024). Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. British Journal of Haematology. 205(3). 1170–1179. 3 indexed citations

Shalhoub, Ruba, Jibran Durrani, Olga Rios, et al.. (2023). Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study. American Journal of Hematology. 98(6). 932–939. 5 indexed citations

Durrani, Jibran & Emma M. Groarke. (2022). Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation. Seminars in Hematology. 59(3). 137–142. 10 indexed citations

Kubota, Yasuo, Jibran Durrani, Wenyi Shen, et al.. (2022). Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 36(12). 2827–2834. 8 indexed citations

Gurnari, Carmelo, Amy C. Graham, Simona Pagliuca, et al.. (2020). Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells Molecules and Diseases. 87. 102528–102528. 7 indexed citations

Durrani, Jibran, Wenyi Shen, Vera Ademà, et al.. (2020). Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. Blood. 136(Supplement 1). 1–1. 1 indexed citations

Durrani, Jibran & Jaroslaw P. Maciejewski. (2019). Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology. 2019(1). 97–104. 23 indexed citations

10.

Awada, Hassan, Jibran Durrani, Tariq Kewan, et al.. (2019). Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?. Blood. 134(Supplement_1). 1404–1404. 1 indexed citations

11.

Awada, Hassan, Ashwin Kishtagari, Teodora Kuzmanovic, et al.. (2019). Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia. Blood. 134(Supplement_1). 2720–2720. 5 indexed citations

12.

Kishtagari, Ashwin, Hassan Awada, Reda Z. Mahfouz, et al.. (2019). Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity. Blood. 134(Supplement_1). 1279–1279. 2 indexed citations

13.

Awada, Hassan, Teodora Kuzmanovic, Ashwin Kishtagari, et al.. (2019). Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia. Blood. 134(Supplement_1). 1405–1405. 2 indexed citations

14.

Durrani, Jibran, Hassan Awada, Wenyi Shen, et al.. (2019). FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults. Blood. 134(Supplement_1). 452–452. 2 indexed citations

15.

Awada, Hassan, Reda Z. Mahfouz, Ashwin Kishtagari, et al.. (2019). Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies. British Journal of Haematology. 188(6). 924–929. 11 indexed citations

16.

Hong, Sanghee, Cassandra M Kerr, Lisa Rybicki, et al.. (2019). Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood. 134(Supplement_1). 2716–2716. 2 indexed citations

17.

Durrani, Jibran, et al.. (2018). To be or not to be a case of heparin resistance. Journal of Community Hospital Internal Medicine Perspectives. 8(3). 145–148. 32 indexed citations

18.

Durrani, Jibran, et al.. (2018). A case of madness resulting in a fortunate outcome; case report of a psychotic break as a result of cortisol secreting thymic neuroendocrine thymic tumor. Journal of Community Hospital Internal Medicine Perspectives. 8(1). 38–41. 2 indexed citations

19.

Channa, Roomasa, et al.. (2010). Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East African Journal of Ophthalmology. 17(3). 264–264. 14 indexed citations

20.

O’Rourke, James, et al.. (1972). Uveoretinal Uptake of <sup>69m</sup>Zn. Ophthalmic Research. 3(5). 289–297. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact